|
Molecular properties generated using the CDK |
Classification ![]() |
|
Compound class | Synthetic organic |
IUPAC Name ![]() |
N-[2-(diethylamino)ethyl]-2,4-dimethyl-5-[[2-oxo-5-(2-phenyl-1,3-thiazol-4-yl)-1H-indol-3-ylidene]methyl]-1H-pyrrole-3-carboxamide |
International Nonproprietary Names ![]() |
|
INN number | INN |
10119 | amcasertib |
Synonyms ![]() |
BBI-503 | BBI503 |
Comments |
Amcasertib (BBI503) is a first-in-class, orally active, cancer stemness kinase inhibitor has been developed by Boston Biomedical for potential anticancer activity [1]. by targeting certain kinase enzymes it is reported to inhibit Nanog (NANOG; Q9H9S0) and other signalling pathways that control stem-cell replication, survival and differentiation. To date (April 2018) the only reports of BBI503 mechanism of action and clinical efficacy are in the form of meeting abstracts, and not in peer reviewed articles. Amcasertib is one of the chemical structures claimed in patent US8299106B2 [2], which were discussed as potential PDGFRα inhibitors therein. |
Database Links ![]() |
|
CAS Registry No. | 1129403-56-0 (source: WHO INN record) |
GtoPdb PubChem SID | 363894218 |
PubChem CID | 74403975 |
Search Google for chemical match using the InChIKey | QDWKGEFGLQMDAM-UHFFFAOYSA-N |
Search Google for chemicals with the same backbone | QDWKGEFGLQMDAM |
Search PubMed clinical trials | amcasertib |
Search PubMed titles | amcasertib |
Search PubMed titles/abstracts | amcasertib |
Search UniChem for chemical match using the InChIKey | QDWKGEFGLQMDAM-UHFFFAOYSA-N |
Search UniChem for chemicals with the same backbone | QDWKGEFGLQMDAM |